Abstract: Treatments for human subjects exposed to, potentially exposed to, infected by, or potentially infected by a coronavirus, such as SARS-CoV-2, its variants and sub variants are described, which are based on an administration of combination drug products having two or three active ingredients formulated with one or more pharmaceutically acceptable carriers. These patients (children, adults and the elderly) suffer from symptoms of COVID-19, and some may continue to suffer from its aftereffects many weeks or months after an infection, like long COVID, including neurological aymptoms such as brain fog and confusion. Physiological ailments may consist of symptoms such as fatigue, shortness of breath, difficulty breathing, joint and muscle aches, and the like. The two-component combination drug product comprises effective amounts of ANTABUSE (disulfiram) and PURINETHOL (mercaptopurine, 6-mercaptopurine, or 6-MP) or its prodrug IMURAN (azathioprine) or hydrates of these compounds.

Abstract: Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).

Abstract: The present disclosure provides methods for the treatment of infections with Mycobacterium such as tuberculosis or leprosy.

Abstract: The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.

Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.

Abstract: This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.

Abstract: The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.

Abstract: A 6?-(4-bromophenyl)-2?-methoxy-3,4?-bipyridine-3?-carbonitrile as antioxidant compound, its synthesis, and its use as an antioxidant agent.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: Provided herein are compositions for reducing symptoms of post-traumatic stress disorder. The compositions include a combination of an N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-depression agent.

Abstract: The present invention provides relatively low pH, stable, pharmaceutically acceptable and ophthalmologically suitable compositions comprising effective amounts of pilocarpine and brimonidine compounds for treating an ocular condition, wherein compositions demonstrate a significant difference in the amount or rate of one or more pharmaceutical ingredient(s) absorbed or retained by ocular tissue or compared to reference composition(s) with similar compositional characteristics but having a significantly higher pH. In aspects compositions are characterizable by other elements, e.g., the inclusion of benzalkonium chloride, a limited amount of sodium chloride, or both. In embodiments, compositions are free of both a borate and a citrate buffer. Compositions provided by the invention surprisingly demonstrate pharmaceutically acceptable stability when stored under controlled room temperature conditions for an extended period of time.

Abstract: A 2-(4-chlorophenyl)-4,5-bis(4-chlorophenyl)-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.

Abstract: A 6?-(2-chlorophenyl)-2?-ethoxy-3,4?-bipyridine-3?-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The present invention relates to compositions and methods for treating vascular Ehlers Danlos Syndrome and associated connective tissue disorders.

Abstract: Compounds, compositions and method of using these compounds are disclosed for treating a disease or disorder in which it is desirable to inhibit BAX, such as a cardiovascular disease or disorder.

Abstract: This invention relates to methods and compositions for treatment of inv (16) leukemia and particularly to treatment of acute myeloid leukemia. Disclosed is a method of treating inv (16) leukemia comprising the step of administering to a subject in in need thereof a therapeutically effective combination of a) a compound of the formula (1) (1) and b) a BRD4 inhibitor selected from the group consisting of JQ1, CeMMECZ, 1-BET 151 (or GSK1210151A), 1-BET 762 (or GSK525762), PFI-1, bromosporine, OTX-015 (or MK-8628), TEN-010, CPI-203, CPI-0610, RVX-208, BI2536, TG101348, LY294002, ABBV-075 (or mivebresib), FT-1101, ZEN003694, pharmaceutically acceptable salts and mixtures thereof. The therapeutically effective combination synergistically inhibits proliferation of inv (16) leukemia cells. This invention also relates to pharmaceutical compositions comprising a therapeutically effective combination of the compound of formula (1) and the BRD4 inhibitor and a pharmaceutically acceptable excipient.

Abstract: The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide. eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.

Abstract: An 2-(2-ethoxyethoxy)-6-(4-hydroxyphenyl)-4-(4-methylphenyl)nicotinonitrile compound, its synthesis, and its use as an antimicrobial agent.

Abstract: Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.

Abstract: The present invention provides uses of an andrographolide derivative in preparation of a medicament for preventing and treating inflammatory bowel disease. The andrographolide derivative AL-1 has the mechanisms, for the treatment of ulcerative colitis, of scavenging of free radicals, inhibition of NF-?B signaling pathway activation and COX-2 expression, activation of PPAR-? expression, and thus can prevent the transcription and expression of inflammatory-related genes to improve the conditions of inflammation. AL-1 can be used as a medicine for the treatment of inflammatory bowel disease and can be formulated to various dosage forms with a pharmaceutically acceptable carrier.